2024 ESMO Annual Meeting Insights Hub
Avatar

ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR

By 2024 ESMO Annual Meeting Insights Hub FEATURING Petros Grivas
By 2024 ESMO Annual Meeting Insights Hub FEATURING Petros Grivas
141 views
September 20, 2024
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
09:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
21:08
Integrity CE

Updates in the Treatment and Management of Bladder Cancer

Feat. M. Galsky, B. Guercio
15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
17:32
Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

15:28
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
09:40
UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Feat. V. Koshkin
19:30
Scripps Health

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas
06:01
ecancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…

Feat. T. Powles
25:32
Memorial Sloan Kettering Cancer Center

Multidisciplinary Approaches for Muscle Invasive Bladder Cancer

Feat. B. Bochner
30:03
UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander
11:29
Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles